Paul Mahon Sells 8,300 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of the stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $517.05, for a total transaction of $4,291,515.00. Following the sale, the executive vice president owned 45,172 shares of the company’s stock, valued at approximately $23,356,182.60. This represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

United Therapeutics Price Performance

NASDAQ UTHR opened at $538.84 on Friday. United Therapeutics Corporation has a 1 year low of $292.34 and a 1 year high of $609.35. The stock has a market capitalization of $23.11 billion, a PE ratio of 19.28, a PEG ratio of 1.81 and a beta of 0.59. The business’s 50-day moving average is $539.43 and its 200 day moving average is $534.22.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. During the same quarter in the prior year, the company posted $6.41 EPS. United Therapeutics’s quarterly revenue was down 1.9% compared to the same quarter last year. As a group, equities research analysts anticipate that United Therapeutics Corporation will post 26.18 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on UTHR. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Bank of America decreased their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. Morgan Stanley set a $515.00 price objective on United Therapeutics in a research report on Thursday. Raymond James Financial assumed coverage on United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 target price on the stock. Finally, TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $646.00.

Institutional Investors Weigh In On United Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new stake in shares of United Therapeutics during the second quarter valued at approximately $2,868,735,000. Wellington Management Group LLP raised its holdings in United Therapeutics by 74.5% in the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after acquiring an additional 1,042,711 shares during the last quarter. Norges Bank bought a new position in United Therapeutics in the 4th quarter valued at approximately $293,418,000. Avoro Capital Advisors LLC lifted its position in United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after acquiring an additional 383,838 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its stake in United Therapeutics by 75.1% during the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock valued at $387,801,000 after purchasing an additional 341,383 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Quarterly earnings exceeded expectations. United Therapeutics reported second-quarter EPS of $7.27, above the roughly $6.86 consensus and up from $6.41 a year earlier. Strong profitability, including a net margin above 40%, provides a favorable fundamental backdrop. United Therapeutics Q2 Earnings Beat Estimates
• Positive Sentiment: Pipeline milestones are offsetting near-term product concerns. Investors are focusing on progress for ralinepag, including its Phase 3 milestone and regulatory applications. The program could provide a new growth driver and reduce reliance on Tyvaso amid competitive pressures. EPS Strength and Ralinepag’s Phase 3 Milestone
• Positive Sentiment: Analyst sentiment remains favorable. H.C. Wainwright reiterated a Buy rating with a $660 price target. RBC maintained an Outperform rating and set a $677 target, despite reducing its previous target from $704. These targets indicate continued confidence in United Therapeutics’ longer-term prospects. Buy Rating Reiterated on United Therapeutics
• Neutral Sentiment: Revenue fell short of estimates. Second-quarter revenue was $783.3 million, below the $804.65 million consensus and down 1.9% year over year. The revenue miss highlights near-term pressure even as earnings and pipeline updates were encouraging. United Therapeutics Q2 Earnings Results
• Negative Sentiment: Senior executives sold sizable positions. CEO Martine Rothblatt sold 9,500 shares for approximately $4.9 million, while EVP Paul Mahon sold 8,300 shares for about $4.3 million. The transactions may reflect personal or scheduled sales, but the reductions in insider ownership could weigh on investor sentiment. United Therapeutics Insider Selling

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.